Understanding how ARID1A mutations affect ovarian cancer treatment
Metabolic basis of ARID1A-mutated ovarian cancer
This study is looking at how certain changes in a gene called ARID1A affect ovarian cancer and whether a new treatment that combines a special drug with immune therapy can help patients with this type of cancer feel better, especially since their cancer often doesn't respond well to regular treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10986968 on NIH RePORTER |
What this research studies
This research investigates the role of ARID1A mutations in ovarian cancer, particularly focusing on how these mutations create a dependence on glutamine metabolism. The study aims to develop a new treatment strategy that combines a glutaminase inhibitor with immune checkpoint blockade therapy, specifically targeting anti-PD-L1. By exploring the mechanisms behind this metabolic dependence, the researchers hope to enhance the effectiveness of treatments for patients with ARID1A-mutated ovarian cancers, which are often resistant to standard therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with ARID1A-mutated ovarian clear cell or endometrioid carcinomas.
Not a fit: Patients without ARID1A mutations or those with other types of ovarian cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with ARID1A-mutated ovarian cancers.
How similar studies have performed: Other research has shown promising results with similar approaches in targeting metabolic pathways in cancer treatment, indicating potential for success in this novel strategy.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Zhang, Rugang — University of Tx Md Anderson Can Ctr
- Study coordinator: Zhang, Rugang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.